Experimental designs for small randomised clinical trials: An algorithm for choice

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Cornu, Catherine ^a,b,c   Kassai, Behrouz ^a,b,c   Fisch, Roland ^d   Chiron, Catherine ^e   Alberti, Corinne ^f,g,h   Guerrini, Renzo ⁱ   Rosati, Anna ⁱ   Pons, Gerard ^f   Tiddens, Harm ^j   Chabaud, Sylvie ^k   Caudri, Daan ^j   Ballot, Clément ^c   Kurbatova, Polina ^c   Castellan, Anne Charlotte ^c   Bajard, Agathe ^k   Nony, Patrice ^b,c  

^a LOUIS PRADEL HOSPITAL   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d NOVARTIS PHARMA AG   (Switzerland)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g HÔPITAL ROBERT DEBRÉ   (France)

^h INSERM   (France)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

^j SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^k CENTRE LÉON BÉRARD   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; COMPARATIVE EFFECTIVENESS; DECISION MAKING; HUMAN; OUTCOME ASSESSMENT; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAFETY; STUDY DESIGN; SYSTEMATIC REVIEW;

ALGORITHMS; CROSS-OVER STUDIES; EUROPEAN UNION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84875360328     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-48     Document Type: Review

References (56)

1. CHMP: guideline on clinical trials in small populations (CHMP/EWP/83561/2005) 2012 http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003615.pdf Accessed on: 9 October
2. EURORDIS, What is a rare disease? 2011 http://www.eurordis.org/content/ what-rare-disease: Accessed on: 31 October
3. The Council of the European Union, Council recommendation of 8 june 2009 on an action in the field of rare diseases 2013 2009/C 151/02 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010: EN:PDF Accessed on: 17 February
4. World Health Organisation, International statistical classification of diseases and related health problems 10 revision 2010 http://www.who.int/ classifications/icd/ICD10Volume2-en-2010.pdf Accessed on: 17 February 2013
5. EURORDIS, Rare diseases: understanding this public health priority'. european organisation for rare diseases 2013 http://www.eurordis.org/IMG/pdf/ princeps-document-EN.pdf: Accessed on: 17 February 18053127
6. Jones B, Kenward MG, Design and analysis of cross-over trials London: Chapman and Hall 2003
7. Euopean Parliament, Regulation (EC) No 1901/2006 of the European parliament and of the council of 12 December 2006 on medicinal products for paediatric use 2012 http://ec.europa.eu/health/files/eudralex/vol-1/reg-2006- 1901/reg-2006-1901-en.pdf Accessed on: 9 October
8. Spilker B, Guide to clinical trials New York: Raven 1991
9. Institute of Medicine, Small clinical trials: issues and challenges Washington DC: National Academy Press 2001
10. Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. Bhattaram VA, Siddiqui O, Kapcala LP, Gobburu JVS, AAPS J 2009 11 456 464 10.1208/s12248-009-9123-2 19521783
11. The stepped wedge trial design: a systematic review. Brown CA, Lilford RJ, BMC Med Res Method 2006 6 54 10.1186/1471-2288-6-54
12. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Clarke CE, Mov Disord 2008 23 784 789 10.1002/mds.21918 18175348
13. The randomized placebo-phase design for clinical trials. Feldman B, Wang E, Willanc A, Szalai JP, J Clin Epidemiol 2001 54 550 557 10.1016/S0895-4356(00) 00357-7 11377114 (Pubitemid 32453347)
14. N of 1 randomised trials for investigating new drugs. Guyatt GH, Heyting A, Jaeschke R, Keller J, Adachi JD, Roberts RS, Control Clin Trials 1990 11 88 100 10.1016/0197-2456(90)90003-K 2161315 (Pubitemid 20136183)
15. A three-stage clinical trial design for rare disorders. Honkanen VE, Siegel AF, Szalai JP, Berger V, Feldman BM, Siegel JN, Stat Med 2001 20 3009 3021 10.1002/sim.980 11590629 (Pubitemid 32982525)
16. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E, N Engl J Med 2009 361 1268 1278 10.1056/NEJMoa0809335 19776408
17. Randomized play-the-winner clinical trials: review and recommendations. Rosenberger W, Control Clin Trials 1999 20 328 342 10.1016/S0197-2456(99)00013-6 10440560 (Pubitemid 29320022)
18. Drop-the-losers design: normal case. Sampson AR, Sill MW, Biom J 2005 47 257 268 10.1002/bimj.200410119 16053251 (Pubitemid 40977266)
19. Using N-of-1 trials to improve patient management and save costs. Scuffham PA, Nikles J, Mitchell GK, Yelland MJ, Vine N, Poulos CJ, Pillans PI, Bashford G, del Mar C, Schluter PJ, Glasziou P, J Gen Intern Med 2010 25 906 913 10.1007/s11606-010-1352-7 20386995
20. Exact group-sequential designs for clinical trials with randomized play-the-winner allocation. Stallard N, Rosenberger WF, Stat Med 2002 21 467 480 10.1002/sim.998 11836730 (Pubitemid 34141371)
21. A generalized drop-the-loser rule for multi-treatment clinical trials. Sun R, Cheung S, Zhang L, J Stat Plan Inference 2007 137 2011 2023 10.1016/j.jspi.2006.06.039
22. A generalized drop-the-loser urn for clinical trials with delayed responses. Zhang LX, Chan WC, Cheung SH, Hu F, Stat Sin 2007 17 387 409
23. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. Zucker DR, Schmid CH, McIntosh MW, D'Agostino RB, Selker HP, Lau J, J Clin Epidemiol 1997 50 401 410 10.1016/S0895-4356(96)00429-5 9179098 (Pubitemid 27223269)
24. A guide to the design and analysis of small clinical studies. Kianifard F, Islam MZ, Pharm Stat 2010 10 363 368 21140524
25. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu L-M, Jacoby R, for the DART-AD investigators, Lancet Neurol 2009 8 151 157 10.1016/S1474-4422(08)70295-3 19138567
26. Vigabatrin withdrawal randomized study in children. Chiron C, Dulac O, Gram L, Epilepsy Res 1996 25 209 215 10.1016/S0920-1211(96)00028-9 8956918 (Pubitemid 26394542)
27. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O, Epilepsy Res 1997 26 389 395 10.1016/S0920-1211(96)01006-6 9095401 (Pubitemid 27117815)
28. Stiripentol in severe Myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, Dulac O, Pons G, Lancet 2000 356 1638 1642 10.1016/S0140-6736(00)03157-3 11089822
29. Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. Chiron C, Tonnelier S, Rey E, Brunet ML, Tran A, d'Athis P, Vincent J, Dulac O, Pons G, J Child Neurol 2006 21 496 502 16948934 (Pubitemid 44069799)
30. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS clinical trials group protocol 076 study group. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy JF, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J, Pediatric AIDS, Clinical Trials Group Protocol 076 Study Group, N Engl J Med 1994 331 1173 1180 10.1056/NEJM199411033311801 7935654 (Pubitemid 24331334)
31. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Guazzi M, Vicenzi M, Arena R, Guazzi MD, Circulation 2011 124 164 174 10.1161/CIRCULATIONAHA.110. 983866 21709061
32. n of 1 trial for an ornithine transcarbamylase deficiency carrier. Hackett A, Gillard J, Wilcken B, Mol Genet Metab 2008 94 157 161 10.1016/j.ymgme.2008.02.001 18343177
33. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Isenberg DA, Allen E, Farewell V, D'Cruz D, Alarcon GS, Aranow C, Bruce IN, Dooley MA, Fortin PR, Ginzler EM, Gladman DD, Hanly JG, Inanc M, Kalunian K, Khamashta M, Merrill JT, Nived O, Petri M, Ramsey-Goldman R, Sturfelt G, Urowitz M, Wallace DJ, Gordon C, Rahman A, Ann Rheum Dis 2010 70 54 59 20833737
34. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. Jaeschke R, Adachi J, Guyatt G, Keller J, Wong B, J Rheumatol 1991 18 447 451 1856813
35. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Kawut SM, Bagiella E, Lederer DJ, Shimbo D, Horn EM, Roberts KE, Hill NS, Barr RG, Rosenzweig EB, Post W, Tracy RP, Palevsky HI, Hassoun PM, Girgis RE, Circulation 2011 123 2985 2993 10.1161/ CIRCULATIONAHA.110.015693 21593252
36. Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P, Arthritis Rheum 2010 62 917 928 20131276
37. N-of-1 double-blind, randomized controlled trial of tramadol to treat chronic cough. Louly PG, Medeiros-Souza P, Santos-Neto L, Clin Ther 2009 31 1007 1013 10.1016/j.clinthera.2009.05.015 19539101
38. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK, N Engl J Med 2000 342 763 769 10.1056/NEJM200003163421103 10717011 (Pubitemid 30151920)
39. Randomized, double blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. Natelson BH, Cheu J, Pareja J, Ellis SP, Policastro T, Findley TW, Psychopharmacology (Berl) 1996 124 226 230 10.1007/BF02246661 (Pubitemid 26129270)
40. A randomized trial of amantadine in huntington disease. O'Suilleabhain P, Dewey RB, Arch Neurol 2003 60 996 998 10.1001/archneur.60.7.996 12873857 (Pubitemid 36858360)
41. A controlled, randomized, delayed-start study of rasagiline in early parkinson disease. Parkinson Study Group, Arch Neurol 2004 61 561 566 10.1001/archneur.61.4.561 15096406 (Pubitemid 38923747)
42. Sirolimus therapy to halt the progression of ADPKD. Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, Ondei P, Rubis N, Diadei O, Gherardi G, Prandini S, Panozo A, Bravo RF, Carminati S, De Leon FR, Gaspari F, Cortinovis M, Motterlini N, Ene-Iordache B, Remuzzi A, Remuzzi G, J Am Soc Nephrol 2010 21 1031 1040 10.1681/ASN.2009121302 20466742
43. Safety of enoxaparin and dextran-70 in the prevention of venous thromboembolism in digestive surgery. A play-the-winner-designed study. Reiertsen O, Larsen S, Storkson R, Trondsen E, Lovig T, Andersen OK, Lund H, Mowinckel P, Scand J Gastroenterol 1993 28 1015 1020 10.3109/00365529309098302 7506841 (Pubitemid 23312250)
44. Characterization of 'winners' to enoxaparin in the prevention of postoperative venous thromboembolism in digestive surgery. Reiertsen O, Mowinckel P, Bjerkeseth O, Lovig T, Thorsen G, Gerner T, Lotveit T, Larsen S, Scand J Gastroenterol 1996 31 616 621 10.3109/00365529609009137 8789903 (Pubitemid 26196145)
45. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Singh T, Rohit M, Grover A, Malhotra S, Vijayvergiya R, Am Heart J 2006 151 851 e855
46. Responders and non-responders to post-operative pain treatment: the loading dose predicts analgesic needs. Stamer UM, Grond S, Maier C, Eur J Anaesthesiol 1999 16 103 110 10101626 (Pubitemid 29123558)
47. Plasma exchange for induction and cyclosporine a for maintenance of remission in Wegener's granulomatosis-a clinical randomized controlled trial. Szpirt WM, Heaf JG, Petersen J, Nephrol Dial Transplant 2011 26 206 213 10.1093/ndt/gfq360 20577017
48. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group, N Engl J Med 1991 324 150 154 1984192
49. The gambia hepatitis intervention study. The Gambia Hepatitis Study Group, Cancer Res 1987 47 5782 5787 2822233
50. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric rheumatology collaborative study group. Giannini EH, Lovell DJ, Silverman ED, Sundel RP, Tague BL, Ruperto N, J Rheumatol 1996 23 919 924 8724309 (Pubitemid 26160254)
51. Evaluation of enoxaparin given before and after operation to prevent venous thromboembolism during digestive surgery: play-the-winner designed study. Bjerkeset O, Larsen S, Reiertsen O, World J Surg 1997 21 584 589 10.1007/s002689900277 9230654 (Pubitemid 27268553)
52. A framework for applying unfamiliar trial designs in studies of rare diseases. Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM, J Clin Epidemiol 2011 64 1085 1094 10.1016/j.jclinepi.2010.12.019 21530171
53. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: opportunities and limitations. Jennison C, Turnbull BW, Biom J 2006 48 650 655 discussion 660-652 10.1002/bimj.200610248 16972717 (Pubitemid 44367908)
54. Adaptive seamless designs: selection and prospective testing of hypotheses. Jennison C, Turnbull BW, J Biopharm Stat 2007 17 1135 1161 10.1080/10543400701645215 18027222 (Pubitemid 350135845)
55. A review of phase 2-3 clinical trial designs. Thall PF, Lifetime Data Anal 2008 14 37 53 10.1007/s10985-007-9049-x 17763973
56. PRIOMEDCHILD ERA-NET programme 2012 http://www.priomedchild.eu/fileadmin/ cm/wetenschap-en-innovatie/priomedchild/new-Predicting-the-best-way-to-test-new- drugs.pdf Accessed on: 18 June